Remote consent and tele-screening so the first trial visit is a video call
Much of trial screening is paperwork, questions and reviewing scans that already exist. Doing this by video and electronic consent before any travel would let patients decide without a wasted trip.
Sites adopt electronic consent with teach-back, tele-screening visits reviewing existing imaging and pathology via central read, and remote collection of history and performance status, so in-person attendance is needed only for procedures the protocol genuinely requires. Regulators in the US and EU accept eConsent; adoption in oncology remains low.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
Pages like this
not linked directly; found by shared links- IdeaPay oncologists for the time it takes to enrol a patient
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trials enrol too few, too slowly.
- IdeaCommunity health workers and trusted local organisations paid to recruit for trials
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaAt least a third of pivotal-trial sites in community and rural settings
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaRemove blanket exclusions for mental illness and dementia; support consent instead
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaMobile research units bring trial visits to rural towns
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaEvery payer covers routine care costs for trial participants, in every country
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaLay trial navigators funded per centre, evaluated in a randomised trial
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaStop excluding people with a prior cancer, controlled HIV, or treated hepatitis
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).